Table 2.
Adverse events (AEs) and serious adverse events (SAEs) by diagnosis*
| CTD-associated PAH
|
Idiopathic PAH (n = 1,654) | P, all CTD-associated PAH vs. idiopathic PAH | |||
|---|---|---|---|---|---|
| All (n = 716) | SSc-associated PAH (n = 407) | Non–SSc-associated PAH (n = 309) | |||
| AE | |||||
| Occurrence of at least 1 AE, % | 84 | 87 | 79 | 81 | 0.20 |
| AEs per person, median (IQR) no. | 3 (1–7) | 3 (1–7) | 3 (1–6) | 3 (1–6) | 0.87 |
| SAE | |||||
| Occurrence of at least 1 SAE, % | 19 | 20 | 17 | 14 | <0.001 |
| SAEs per person, % | <0.001 | ||||
| 0 | 81 | 80 | 83 | 86 | |
| 1 | 14 | 14 | 13 | 9 | |
| >1 | 5 | 6 | 4 | 5 | |
*
CTD-associated PAH = connective tissue disease–associated pulmonary arterial hypertension; SSc = systemic sclerosis; IQR = interquartile range.